| Literature DB >> 23838996 |
Ganji Purnachandra Nagaraju1, Purnachandra Nagaraju Ganji1, Wungki Park, Jing Wen, Hemchandra Mahaseth, Jerome Landry, Alton B Farris, Field Willingham, Patrick S Sullivan, David A Proia, Iman El-Hariry, Latonia Taliaferro-Smith, Roberto Diaz, Bassel F El-Rayes.
Abstract
Hypoxia-inducible factors (HIFs) and STAT-3 play essential roles in angiogenesis. HIF-1α and STAT-3 are clients of the heat shock protein 90 (HSP90). We hypothesized that ganetespib, a potent HSP90 inhibitor, would disrupt angiogenesis in colorectal cancer (CRC) through inhibition of HIF-1α and STAT-3. CRC cell lines (HCT116 and HT29) were used in all the experiments. Egg CAM and HUVEC assays revealed decreased angiogenesis in ganetespib treated cell lines. Ganetespib inhibited matrigel plug vascularization and tumor growth of xenografts. Significant inhibition of PDGFA, FGF2, Ang-1, Ang-2, TGFβ1, VEGF, HIF-1α and STAT-3 expression was observed in both cell lines treated ganetespib. HIF-1α overexpression resulted in the increase VEGF and STAT-3 expression and this was inhibited by ganetespib. HIF-1α knockdown inhibited VEGF and STAT-3 expression. STAT-3 knockdown inhibited VEGF but not HIF-1α expression. HSP90, STAT-3 and VEGF expression was significantly higher in CRC compared to adjacent normal tissue. Significant downregulation of PDGFA, FGF2, Ang-1, Ang-2, TGFβ1, VEGF, STAT-3 and HIF-1α mRNA was observed in the post ganetespib treatment tumor samples from patients with rectal cancer. These results collectively suggest that inhibition of HSP90 is a promising antiangiogenic strategy in CRC. HSP90 angiogenic effects are mediated through HIF-1α and STAT-3.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23838996 DOI: 10.1007/s10456-013-9364-7
Source DB: PubMed Journal: Angiogenesis ISSN: 0969-6970 Impact factor: 9.596